1,6-naphthyridine-3-carboxylic acid ethyl ester | 250674-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,6-naphthyridine-3-carboxylic acid ethyl ester
• 英文别名: Ethyl 1,6-naphthyridine-3-carboxylate
• CAS: 250674-52-3
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: IILBQUWQOOQDNM-UHFFFAOYSA-N

物化性质

• 沸点：
  333.1±22.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,6-naphthyridine-3-carboxylic acid ethyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 1,6-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors

  摘要：

  Structure-activity relationship studies on our newly identified anti-HCMV compounds, the 1,6-naphthyridines led to the identification of isoquinoline-6-carboxamides as potent and selective anti-HCMV agents. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00435-7
• 作为产物：
  描述：

  ethyl 4-chloro-1,6-naphthyridine-3-carboxylate 在 四(三苯基膦)钯 、 sodium formate 作用下， 以 二甲基亚砜 为溶剂， 生成 1,6-naphthyridine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Isoquinoline-6-carboxamides as potent and selective anti-human cytomegalovirus (HCMV) inhibitors

  摘要：

  Structure-activity relationship studies on our newly identified anti-HCMV compounds, the 1,6-naphthyridines led to the identification of isoquinoline-6-carboxamides as potent and selective anti-HCMV agents. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00435-7

文献信息

• Chemical compounds as H—PGDS inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US11149035B2

  公开（公告）日：2021-10-19

  A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  式 (I) 的化合物 其中 R1、R2、R3、R4、X、Y 和 A 如本文所定义。 本发明的化合物是血液前列腺素 D 合酶（H-PGDS）的抑制剂，可用于治疗杜氏肌营养不良症。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物抑制 H-PGDS 活性和治疗与之相关疾病的方法。
• Chemical Compounds as H-PGDS Inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20200123152A1

  公开（公告）日：2020-04-23

  A compound of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.